Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cost-Effectiveness of Atrioventricular Synchronous Leadless Pacing in Patients With Atrioventricular Block: Results and Implications From an Exploratory Analysis for Japan.

Circulation reports·2026
Same author

Cross-country comparison of perinatal outcomes between japanese mothers in the united states and japan: a cross-sectional study.

BMJ public health·2026
Same author

Targeting JAK/STAT With Ruxolitinib in Acute Fulminant Myocarditis.

Journal of cardiac failure·2026
Same author

Sudden Cardiac Death and its Relation to Previously Diagnosed or Occult Cardiac Disease at Autopsy.

Journal of the American College of Cardiology·2026
Same author

Sudden Cardiac Death Due to Myocardial Infarction With Obstructive and Nonobstructive Coronary Arteries.

Journal of the American College of Cardiology·2026
Same author

A novel theoretical model and experimental validation of backup force in percutaneous coronary intervention.

Cardiovascular intervention and therapeutics·2026

Related Experiment Video

Updated: Jul 7, 2026

Design of a Biocompatible Drug-Eluting Tracheal Stent in Mice with Laryngotracheal Stenosis
08:26

Design of a Biocompatible Drug-Eluting Tracheal Stent in Mice with Laryngotracheal Stenosis

Published on: January 21, 2020

Introducing the first polymer-free leflunomide eluting stent.

Tobias Deuse1, Reinhold G Erben, Fumiaki Ikeno

  • 1Department of Cardiothoracic Surgery, Stanford University School of Medicine, 300 Pasteur Dr., CVRB MC 5407, Stanford, CA, USA.

Atherosclerosis
|February 26, 2008
PubMed
Summary

A polymer-free leflunomide-eluting stent demonstrated comparable efficacy to a rapamycin-eluting stent in reducing neointima formation. Leflunomide

More Related Videos

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

4D Printed Bifurcated Stents with Kirigami-Inspired Structures
06:52

4D Printed Bifurcated Stents with Kirigami-Inspired Structures

Published on: July 25, 2019

Related Experiment Videos

Last Updated: Jul 7, 2026

Design of a Biocompatible Drug-Eluting Tracheal Stent in Mice with Laryngotracheal Stenosis
08:26

Design of a Biocompatible Drug-Eluting Tracheal Stent in Mice with Laryngotracheal Stenosis

Published on: January 21, 2020

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

4D Printed Bifurcated Stents with Kirigami-Inspired Structures
06:52

4D Printed Bifurcated Stents with Kirigami-Inspired Structures

Published on: July 25, 2019

Area of Science:

  • Cardiovascular Research
  • Biomaterials Science
  • Pharmacology

Background:

  • Investigating novel drug-eluting stents (DES) is crucial for managing coronary artery disease.
  • Polymer-free DES offer potential advantages over traditional polymer-based systems.
  • Leflunomide, an immunosuppressive drug, is explored as an alternative to rapamycin in DES.

Purpose of the Study:

  • To compare the pharmacological characteristics, in vivo efficacy, and in vitro mechanisms of a polymer-free leflunomide-eluting stent (L) against a rapamycin-eluting stent (R).
  • To evaluate the impact of leflunomide and rapamycin on neointima formation and vascular cell proliferation.

Main Methods:

  • Polymer-free stents were coated with leflunomide or rapamycin and implanted in rats.
  • Neointima formation was assessed using optical coherence tomography (OCT) and histopathology at 6 weeks.
  • In vitro proliferation assays were conducted on endothelial cells (EC) and smooth muscle cells (SMC).

Main Results:

  • Both leflunomide and rapamycin stents showed significantly reduced neointima formation compared to bare metal stents (BM).
  • Drug release kinetics were similar for both leflunomide and rapamycin.
  • Leflunomide and rapamycin similarly inhibited SMC proliferation in vitro.
  • Leflunomide did not inhibit EC proliferation, unlike rapamycin.

Conclusions:

  • Polymer-free leflunomide-eluting stents exhibit comparable efficacy to rapamycin-eluting stents in reducing neointima formation.
  • The diminished inhibition of endothelial cell proliferation by leflunomide may enhance arterial healing and improve stent safety.